The current standard of care for GvHD prophylaxis in older patients undergoing transplantation скачать в хорошем качестве

The current standard of care for GvHD prophylaxis in older patients undergoing transplantation

Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the standard of care (SoC) for graft-versus-host disease (GvHD) prophylaxis in older patients undergoing reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). The current SoC regimen combines post-transplant cyclophosphamide (PTCy) at a dose of 50 mg/kg on days +3 and +4 with a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF), and reduces the incidence of clinically significant acute and chronic GvHD compared to CNI-based prophylaxis alone. Dr Abedin also mentions alternative approaches being explored, including adding a JAK inhibitor, such as ruxolitinib, to CNI-based prophylaxis. This interview took place virtually. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.